Skip to main content
Premium Trial:

Request an Annual Quote

Appistry, LifeMap Partner on NGS Data Analysis

NEW YORK (GenomeWeb News) – Cloud computing company Appistry today announced a partnership and reseller agreement to integrate LifeMap Sciences' databases into the outputs of genomics pipelines running on Appistry's Ayrris computing environment.

Under the terms of the deal, St. Louis-based Appistry will market next-generation sequencing analysis outputs and reports that include LifeMap's GeneCards and MalaCards data to clinicians and researchers as part of a revenue-sharing arrangement based on the sales of such reports.

LifeMap is a subsidiary of BioTime and holds the exclusive worldwide license to market GeneCards and MalaCards from Yeda Research and Development, the commercial arm of the Weizmann Institute of Science.

Ayrris supports the rapid assembly of data-intensive analytics running on a customer's tools at scale without requiring specialized expertise in high-performance computing or a complex software development effort, Appistry said.

LifeMap's GeneCards database provides concise genomic information on all known and predicted human genes. MalaCards contains information on a wide array of human diseases and the roles genes play in disease processes.

"To realize the promise of personalized medicine, organizations need to scale their bioinformatics pipelines to handle thousands of patient cases, while also providing information physicians can act on," Appistry CEO Kevin Haar said in a statement. "Our partnership with LifeMap enables medical researchers to extend their analytic processes to deliver a better understanding of the biological pathways and disease states associated with genetic samples."

Financial and other terms of the deal were not disclosed.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.